Lung Cancer

Lung cancer kills more people than any other kind of cancer, even though 10-year survival rates approach 90 percent when detected in the earliest stages. On Wednesday, Medtronic, which operates in Minnesota, touted new study data for its SuperDimension bronchoscope navigation system. It shows the system successfully detected early signs of lung cancer in a good proportion of patients in an all-comers population that included community hospitals and academic medical centers. Data from the NAVIGATE study , published in the Journal of Thoracic Oncology, showed that in U.S. patients who got SuperDimension imaging and biopsies and were diagnosed with cancer, 65 percent of those diagnoses were for Stage I or Stage II cancers. “The ability to diagnose early and stage in a single procedure may improve survival and reduce treatment costs,” study authors wrote . Staging in a single procedure means that a patient can be imaged, biopsied and diagnosed to a specific “stage” of lung cancer with

Share this Article You are free to share this article under the Attribution 4.0 International license. People at high risk of lung cancer are 40 percent more likely to see a doctor when they get help identifying and monitoring their symptoms, a new study shows. Lung cancer is the most common cancer worldwide, with 1.3 million new diagnoses every year. It has one of the lowest survival outcomes of any cancer because more than two-thirds of patients receive a diagnosis too late for curative treatment. Increasing early recognition and earlier diagnosis is vital to improve patient outcomes, researchers say. Behavioral interventions in primary care could play an important role. For the study, which appears in Thorax , people at increased risk of lung cancer due to heavy smoking attended a consultation with a nurse to discuss respiratory symptoms to look out for, and what to do if they had any concerns. Symptoms included: coughing up blood, persistent or worsening cough, bec

A newly-formed partnership between Biodesix and MRM Proteomics could be the key that unlocks the door for better outcomes in lung cancer patients. Earlier this week, the two diagnostic companies announced a deal that would have Montreal-based MRM Proteomics granting Biodesix the rights to use the iMALDI technologies. Boulder, CO-based Biodesix would use iMALDI to further advance its blood-based lung cancer diagnostics. “MRM has long been a leader in developing new tools in proteomics,” David Brunel CEO of Biodesix, told MD+DI . “A partnership with [MRM] allows us to expand the set of tools we use to probe the biology and answer the complex questions.” MRM has existing assays that Biodesix will incorporate into its laboratories in a CLIA setting. That should happen in the next half year. An FDA-approved product would probably be available two-to-four years out – depending on regulatory and reimbursement requirements. “Examining a patient’s genomic data has advanced targeted therapi

NEW YORK (GenomeWeb) – After delays in finalizing its test algorithm and technology platform, OncoCyte said this week that it believes it can launch its non-invasive lung cancer test by the end of this year following strong performance data from its latest internal validation using a population-reflective, blinded sample cohort. Get the full story with GenomeWeb Premium Only $95 for the first 90 days* GenomeWeb Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives Never miss another important industry story. Try GenomeWeb Premium now. You may already have institutional access! Check if I qualify. Already a GenomeWeb or 360Dx Premium member? Login Now . * Before your trial expires, we’ll put together a custom quote with your long-term premium options. http://bit.ly/2RssUYi

The Lung Cancer Master Protocol, or Lung-MAP, will expand to include all patients diagnosed with non-small cell lung cancer. Lung-MAP — the first large-scale precision medicine lung cancer trial backed by the NCI — is supported by a partnership with NCI’s National Clinical Trials Network, SWOG Cancer Research Network, Friends of Cancer Research, the Foundation for the National Institutes of Health, Foundation Medicine, pharmaceutical companies and lung cancer advocacy organizations. The trial previously focused on treatments for advanced-stage squamous cell lung cancer. Allowing all patients with NSCLC — which represents 85% of lung cancer diagnoses in the U.S. — to enroll on the trial means thousands of new patients will be eligible. “We have more than 200,000 new cases of NSCLC in the United States each year, and we desperately need new treatments,” principal investigator Vali A. Papadimitrakopoulou , MD, chief of thoracic medical oncology and professor of medicine at The Univ

Vali Papadimitrakopoulou, MD The Lung Cancer Master Protocol (Lung-MAP), known as the first precision medicine trial in lung cancer supported by the National Cancer Institute (NCI), has expanded to include patients with all types of non–small cell lung cancers (NSCLC), according to SWOG, the organization that manages the trial program. 1 The biomarker-driven, umbrella-design trial, which initially launched in 2014, previously enrolled patients with advanced-stage squamous cell lung cancer. It was originally designed to evaluate 4 novel targeted agents and one immunotherapy agent compared with standard-of-care regimens in separate, randomized substudies. Since its inception, Lung-MAP has registered nearly 2000 patients and is offered at more than 650 medical centers and community hospitals in the United States. The stud http://bit.ly/2RtSpZk

[unable to retrieve full-text content] Lung cancer warning - how the colour of your MUCUS could reveal your risk    Express LUNG cancer symptoms include a cough that won't go away, chest pain and unexplained weight loss. You could be at risk of lung cancer signs if your mucus is ... http://bit.ly/2Uw22J1

[unable to retrieve full-text content] UT/West Institute for Cancer Research offering free lung cancer screenings    WMC MEMPHIS, TN (WMC) - The University of Tennessee/West Institute for Cancer Research is offering free lung cancer screenings in February for qualifying ... http://bit.ly/2CTNtHS

NewsPatrolling.com : Lung cancer is more common in non-smokers than many people realize. Indeed, lung cancer is now considered the most common cause of cancer deaths. In general, 10 percent to 15 percent of lung malignant growths happen in non-smokers.About half of the tumors have mutations that can be targeted by new drugs in people who have never smoked. This may explain why non - smokers with lung cancer tend to live longer with the disease than current and former smokers. Some causes of lung cancer that are not related to tobacco include: 1. Radon: Radon gas exposure in our homes is the main cause of non-smoker lung cancer.Radon gas, a result of uranium separating, can be found noticeable all around us and is commonly innocuous. The danger arises when this naturally occurring radioactive gas in the soil, as in mines and in the lower floors of some homes, is trapped and concentrated.Since radon can't be seen and has no scent, the best way to know whether it's there is to t

Share this Article You are free to share this article under the Attribution 4.0 International license. People at high risk of lung cancer are 40 percent more likely to see a doctor when they get help identifying and monitoring their symptoms, a new study shows. Lung cancer is the most common cancer worldwide, with 1.3 million new diagnoses every year. It has one of the lowest survival outcomes of any cancer because more than two-thirds of patients receive a diagnosis too late for curative treatment. Increasing early recognition and earlier diagnosis is vital to improve patient outcomes, researchers say. Behavioral interventions in primary care could play an important role. For the study, which appears in Thorax , people at increased risk of lung cancer due to heavy smoking attended a consultation with a nurse to discuss respiratory symptoms to look out for, and what to do if they had any concerns. Symptoms included: coughing up blood, persistent or worsening cough, bec

Lung cancer is one of the most common types of cancer to be diagnosed in the UK, according to the NHS. It’s also one of the most serious, as there are usually no symptoms in its early stages. That means it’s usually only diagnosed after the cancer has spread through the lungs or into other parts of the body. But, you could reveal your risk of lung cancer symptoms by checking the colour of your sputum, it’s been revealed. Coughing up rust-coloured sputum - a mix of saliva and mucus - could be a warning sign of lung cancer. You could also be at risk of the condition if you cough up blood, or red-tinged sputum. If you notice any abnormal changes to the colour of your spit, you should speak to a doctor. “Most lung cancers do not cause any symptoms until they have spread, but some people with early lung cancer do have symptoms,” said the American Cancer Society. “If you go to your doctor when you first notice symptoms, your cancer might be diagnosed at an earlier stage, when trea

A little over two years ago, former USA hockey star Rachael Malmberg was diagnosed with stage 4 lung cancer. Malmberg, now 33, was healthy and exercised regularly, so when she started experiencing consistent pain in her back and ribs, she thought nothing of it. Get push notifications with news, features and more. + Follow Following You'll get the latest updates on this topic in your browser notifications. However, when she went to see a doctor, she was hit with the devastating news. Malmberg took her diagnosis as an opportunity to get educated and researched the leading causes of lung cancer. That’s when she discovered radon. “It wasn’t on my radar at all actually until I started doing research on causes of lung cancer. Upon diagnosis I had no idea about radon,” Malmberg told Fox News. Radon is described as a “radioactive gas released from the normal decay of the elements uranium, thorium, and radium in rocks and soil,” according to the National Cancer Insti

A former Olympic hockey player and mother-of-one developed lung cancer after she was exposed to high levels of toxic radon in her homes. Rachael Malmberg, 33, doesn't smoke, and has remained physically active even after retiring from the US Women's ice hockey team.  Yet, at her young age, Rachael was diagnosed with stage four lung cancer.  And the culprit, doctors told her, had been lurking in her own home.   Colorless, odorless but radioactive radon is estimated to cause as many as 20,000 cases of lung cancer in the US every year - including Rachael's.  Rachael Malmberg, 33, was diagnosed with stage 4 lung cancer that was most likely caused by years of exposure to a colorless, odorless gas called radon in her home  On the surface, Rachael hardly fit the profile of an average lung cancer patient.  Most people diagnosed with the devastating disease are over 65 and are often smokers. Lung cancer is less common among women than men and white people are less at ri

A little over two years ago, former USA hockey star Rachael Malmberg was diagnosed with stage 4 lung cancer. Malmberg, now 33, was healthy and exercised regularly, so when she started experiencing consistent pain in her back and ribs, she thought nothing of it. Get push notifications with news, features and more. + Follow Following You'll get the latest updates on this topic in your browser notifications. However, when she went to see a doctor, she was hit with the devastating news. Malmberg took her diagnosis as an opportunity to get educated and researched the leading causes of lung cancer. That’s when she discovered radon. “It wasn’t on my radar at all actually until I started doing research on causes of lung cancer. Upon diagnosis I had no idea about radon,” Malmberg told Fox News. Radon is described as a “radioactive gas released from the normal decay of the elements uranium, thorium, and radium in rocks and soil,” according to the National Cancer Insti

AUSTIN, Texas--(BUSINESS WIRE)--Jan 29, 2019--Asuragen, Inc., a molecular diagnostics company delivering easy-to-use products for complex testing in genetics and oncology, today announced that the results of a five-site study using the QuantideX NGS RNA Lung Cancer Kit * have been published as an article in press by The Journal of Molecular Diagnostics (see https://doi.org/10.1016/j.jmoldx.2018.10.003 ). The peer-reviewed article, titled “Design, Optimization, and Multisite Evaluation of a Targeted Next-Generation Sequencing Assay System for Chimeric RNAs from Gene Fusions and Exon-Skipping Events in Non–Small Cell Lung Cancer,” also describes the design and development of the assay system. This system includes controls, pre-analytical sample QC, targeted RNA-based enrichment, library clean-up and pooling, and companion bioinformatics software that analyzes the corresponding next-generation sequencing (NGS) data. Non-small cell lung cancer (NSCLC) accounts for more than 10% of all

“The overall goal of the project is to try provide insight into the role of environmental factors in lung cancer,” Berger said. “One of the exciting things is that we’re going to be able to observe the broad underlying mutational signatures that are reflective of possible environmental exposures and could contribute to lung cancer risk in people that have never smoked.” The results will be a step toward understanding who among never-smokers may be most at risk for lung cancer and, once validated in further studies, point toward possible preventive and risk-reducing measures. This prevention-focused study complements Berger’s first study of tumors from never-smokers, which focused on understanding how specific mutations may influence cancer treatment response. Both projects draw on samples and data from participants in the Women’s Health Initiative . Fred Hutch is the coordinating hub for this nationwide study. “The WHI has carefully collected information about environmental and occ

Pablo Palacios is a senior in the East Union High boys’ soccer program. Last November, he was diagnosed with lung cancer.  “He normally played on defense for us,” said Lancers coach Ronnie Green of his player, Palacios, according to Green, has been receiving treatments for his condition at UC San Francisco Medical Center. “He’s on his fourth treatment of chemotherapy,” said Green, who indicated that Palacios’ condition continues to improve. Not too long ago, Green and his players put together a GoFundMe account to help the family foot the medical bill. “We raised $4,500,” he added. East Union is continuing its effort to help Palacios. On Thursday, the Lancers will play Sierra High in a Valley Oak League contest at Dino Cunial Field. All of the proceeds for the “Kicking for A Cure” game will assist the Palacios family. According to Green, he borrowed the idea from Manteca High soccer coach Justin Coenenberg, who will host his event of the same name to assist fellow teacher Amy

Lung cancer is the uncontrolled growth of abnormal cells in one or both lungs. These abnormal cells do not carry out the functions of normal lung cells and do not develop into healthy lung tissue. As they grow, the abnormal cells can form tumors and interfere with the functioning of the lung, which provides oxygen to the body via the blood. There are two major types of lung cancer, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Non-small cell lung cancer is more common and accounts for about 85 percent of lung cancers. Staging lung cancer is based on whether the cancer is local or has spread from the lungs to the lymph nodes or other organs. Because the lungs are large, tumors can grow in them for a long time before they are found. Even when symptoms, such as coughing and fatigue, do occur, people think they are due to other causes. For this reason, early-stage lung cancer (stages I and II) is difficult to detect. There are several risk factors that may increas

Eric Vallieres, MD Despite practice-changing advancements with immunotherapy and targeted therapy in the treatment of patients with lung cancer, the importance of surgery remains rigid for now, said Eric Vallieres, MD. In the past few years, thoracic surgery has become more minimal invasivene with the use of video-assisted thoracic surgery (VATS) and, more recently, robotics. Smaller incisions and a more visualized scope of the operation site have allowed for patients to return to a normal quality of life (QoL) in dramatically less time. Vallieres, medical director of the Division of Thoracic Surgery of Swedish Medical Center, explained that in the future, the efficacy of surgery may be enhanced when used in partnership with immunotherapy. For example, ongoing research is looking to determine if adjuvant immunotherapy will have the same impact after the lymph nodes have been removed. Secondly, in a small phase II trial, investigators evaluated the use of neoadjuvant nivolumab (Opd

MEDIA CONTACT Available for logged-in reporters only CITATIONS Genes & Development, Jan-2019 SECTION MEDICINE TYPE OF ARTICLE Research Results Newswise — New Brunswick, N.J. – January 27, 2019 – An energy crisis usually isn’t viewed as a positive situation, but when it comes to stopping a common form of lung cancer, it’s considered a good thing. Research from investigators at Rutgers Cancer Institute of New Jersey examined a potential approach to cancer therapy that disrupts a cancer cell’s ‘fuel supply’ by targeting a cellular survival mechanism known as autophagy.   ‘ Jessie’ Yanxiang Guo, PhD , a resident researcher in the Cancer Metabolism and Growth Program at Rutgers Cancer Institute and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, is the senior author of the work published in the January 28 online edition of Genes & Development  (doi:10.1101/gad.320481.118). She shares more about the research, which focused on lung c

Eric Vallieres, MD Despite practice-changing advancements with immunotherapy and targeted therapy in the treatment of patients with lung cancer, the importance of surgery remains rigid for now, said Eric Vallieres, MD. In the past few years, thoracic surgery has become more minimal invasivene with the use of video-assisted thoracic surgery (VATS) and, more recently, robotics. Smaller incisions and a more visualized scope of the operation site have allowed for patients to return to a normal quality of life (QoL) in dramatically less time. Vallieres, medical director of the Division of Thoracic Surgery of Swedish Medical Center, explained that in the future, the efficacy of surgery may be enhanced when used in partnership with immunotherapy. For example, ongoing research is looking to determine if adjuvant immunotherapy will have the same impact after the lymph nodes have been removed. Secondly, in a small phase II trial, investigators evaluated the use of neoadjuvant nivolumab (Opd

Bristol-Myers Squibb Co. said its fourth-quarter revenue rose on sales of key drugs, and the company expects further growth this year as it works to complete the planned $74 billion acquisition of rival cancer drugmaker Celgene Corp. New York-based Bristol also said Thursday it suffered another setback entering the market to treat newly diagnosed lung-cancer patients, withdrawing its application for U.S. approval of a combination of its Opdivo and Yervoy therapies because more data was needed. The company said it swung to a fourth-quarter profit of $1.2 billion, or 73 cents a share, from a year-earlier loss of $2.3 billion, or $1.42 cents a share. Revenue climbed 10% to $6 billion. Analysts surveyed by FactSet expected a profit of 82 cents a share on $6 billion in revenue. The quarter's results were driven by Bristol's top-selling products, including Opdivo, whose sales rose 33% from a year earlier, and blood thinner Eliquis, which logged a 25% jump in sales. Bristol expe

MEDIA CONTACT Available for logged-in reporters only CITATIONS Genes & Development, Jan-2019 SECTION MEDICINE TYPE OF ARTICLE Research Results Newswise — New Brunswick, N.J. – January 27, 2019 – An energy crisis usually isn’t viewed as a positive situation, but when it comes to stopping a common form of lung cancer, it’s considered a good thing. Research from investigators at Rutgers Cancer Institute of New Jersey examined a potential approach to cancer therapy that disrupts a cancer cell’s ‘fuel supply’ by targeting a cellular survival mechanism known as autophagy.   ‘ Jessie’ Yanxiang Guo, PhD , a resident researcher in the Cancer Metabolism and Growth Program at Rutgers Cancer Institute and an assistant professor of medicine at Rutgers Robert Wood Johnson Medical School, is the senior author of the work published in the January 28 online edition of Genes & Development  (doi:10.1101/gad.320481.118). She shares more about the research, which focused on lung c

Analysts expect EuroDry Ltd. (NASDAQ:EDRY) to report $0.22 EPS on February, 21.EDRY’s profit would be $495,899 giving it 9.18 P/E if the $0.22 EPS is correct. After having $0.62 EPS previously, EuroDry Ltd.’s analysts see -64.52% EPS growth. The stock decreased 2.42% or $0.2 during the last trading session, reaching $8.08. About 2,543 shares traded. EuroDry Ltd. (NASDAQ:EDRY) has 0.00% since January 27, 2018 and is . It has by 0.00% the S&P500. Bollard Group Llc increased Merck & Co Inc (MRK) stake by 6.64% reported in 2018Q3 SEC filing. Bollard Group Llc acquired 6,699 shares as Merck & Co Inc (MRK)’s stock rose 11.30%. The Bollard Group Llc holds 107,528 shares with $7.63 million value, up from 100,829 last quarter. Merck & Co Inc now has $189.70B valuation. The stock decreased 0.30% or $0.22 during the last trading session, reaching $72.95. About 13.41M shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 41.35% since January 27, 2018 and is uptrending. It has

Ever since it received a standing ovation at its world premiere at Sundance , The Farewell   has been a buzzy title at the Park City fest as an emotional dramedy based on director/writer Lulu Wang ’s own story about her grandmother. The filmmaker stopped by the Deadline studio alongside stars Awkwafina , Tzi Ma , and Diana Lin. When Wang learned that her grandmother was diagnosed with stage 4 lung cancer, her mother called her to let her know that she one had three months to live. In China, the doctors don’t share this information with the patient, instead, they tell a family member. In this case, her grandmother’s sister. In order to get everyone to China to be with her ailing grandmother, they planned a wedding and still kept the diagnosis a secret. “I thought it was most ridiculous thing,” Wang told Deadline. “Also, the saddest and funny thing at the same time.” Thus,  The Farewell  was born. The film follows headstrong and emotional writer Billi (Awkwafina) as she rebels again